Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
IGHG2 N/A
Sequence Length (AA) Molecular Weight (Da)
395 43806
Protein Name
Immunoglobulin heavy constant gamma 2
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV
60 70 80 90 100
HTFPAVLQSS GLYSLSSVVT VPSSNFGTQT YTCNVDHKPS NTKVDKTVER
110 120 130 140 150
KCCVECPPCP APPVAGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP
160 170 180 190 200
EVQFNWYVDG VEVHNAKTKP REEQFNSTFR VVSVLTVVHQ DWLNGKEYKC
210 220 230 240 250
KVSNKGLPAP IEKTISKTKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG
260 270 280 290 300
FYPSDISVEW ESNGQPENNY KTTPPMLDSD GSFFLYSKLT VDKSRWQQGN
310 320 330 340 350
VFSCSVMHEA LHNHYTQKSL SLSPELQLEE SCAEAQDGEL DGLWTTITIF
360 370 380 390 395
ITLFLLSVCY SATITFFKVK WIFSSVVDLK QTIVPDYRNM IRQGA

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-675 Collapse assay details

Data source: Panorama

Official Gene Symbol
IGHG2
Peptide Modified Sequence
EEQFN[+1.0]STFR
Modification Type
Deamidated (NQ)
Protein - Site of Modification
176
Peptide - Site of Modification
5
Peptide Start
172
Peptide End
180
CPTAC ID
CPTAC-675
Peptide Molecular Mass
1,157.4989
Species
Homo sapiens (Human)
Assay Type
Enrichment PRM
Enrichment Method
N-linked glycopeptide solid phase extraction
Matrix
serum
Submitting Laboratory
Johns Hopkins University
Submitting Lab PI
Daniel Chan, Hui Zhang, Zhen Zhang

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Q-Exactive (ThermoFisher)
Internal Standard
synthetic peptide
Peptide Standard Purity
Crude
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Dionex UltiMate 3000 RSLCnano LC (ThermoFisher)
Column Packing
Acclaim PepMap100 C18, 5um (Trap); Acclaim PepMap RSLC C18, 2um (Analytical)
Column Dimensions
300um x 5mm (Trap); 75um x 25cm (Analytical)
Flow Rate
0.5 uL/min

Assay Multiplexing Expand assay panel

Johns Hopkins University-A

CPTAC-648:
APMAP.
AGPN[+1.0]GTLFVADAYK
CPTAC-649:
AFM.
DIENFN[+1.0]STQK
CPTAC-650:
AFM.
FN[+1.0]ETTEK
CPTAC-651:
SERPINA1.
YLGN[+1.0]ATAIFFLPDEGK
CPTAC-652:
APOB.
FN[+1.0]SSYLQGTNQITGR
CPTAC-653:
APOB.
YDFN[+1.0]SSM[+16.0]LYSTAK
CPTAC-654:
APOH.
VYKPSAGN[+1.0]NSLYR
CPTAC-655:
BTD.
FN[+1.0]DTEVLQR
CPTAC-656:
CDH13.
IN[+1.0]NTHALVSLLQNLNK
CPTAC-657:
CPB2.
QVHFFVN[+1.0]ASDVDNVK
CPTAC-658:
CTSD.
GSLSYLN[+1.0]VTR
CPTAC-659:
JCHAIN.
EN[+1.0]ISDPTSPLR
CPTAC-660:
CP.
EHEGAIYPDN[+1.0]TTDFQR
CPTAC-661:
CLU.
EDALN[+1.0]ETR
CPTAC-662:
CLU.
LAN[+1.0]LTQGEDQYYLR
CPTAC-663:
DKFZp779M0311.
QSVPAHFVALN[+1.0]GSK
CPTAC-664:
ATRN.
IDSTGN[+1.0]VTNELR
CPTAC-665:
C4A.
FSDGLESN[+1.0]SSTQFEVK
CPTAC-666:
C4A.
GLN[+1.0]VTLSSTGR
CPTAC-667:
C8A.
GGSSGWSGGLAQN[+1.0]R
CPTAC-668:
CD44.
AFN[+1.0]STLPTM[+16.0]AQM[+16.0]EK
CPTAC-669:
IGHG1.
EEQYN[+1.0]STYR
CPTAC-670:
LGALS3BP.
ALGFEN[+1.0]ATQALGR
CPTAC-671:
HP.
VVLHPN[+1.0]YSQVDIGLIK
CPTAC-672:
SERPINA4.
FLN[+1.0]DTM[+16.0]AVYEAK
CPTAC-673:
IGHG4.
EEQFN[+1.0]STYR
CPTAC-674:
IGHA2.
TPLTAN[+1.0]ITK
CPTAC-675:
IGHG2.
EEQFN[+1.0]STFR
CPTAC-676:
ITIH2.
GAFISN[+1.0]FSM[+16.0]TVDGK
CPTAC-677:
ICAM2.
AAPAPQEATATFN[+1.0]STADR
CPTAC-678:
LRG1.
LPPGLLAN[+1.0]FTLLR
CPTAC-679:
LYVE1.
ANQQLN[+1.0]FTEAK
CPTAC-680:
TIMP1.
FVGTPEVN[+1.0]QTTLYQR
CPTAC-681:
LCN2.
SYN[+1.0]VTSVLFR
CPTAC-682:
KLKB1.
IYPGVDFGGEELN[+1.0]VTFVK
CPTAC-683:
KLKB1.
IYSGILN[+1.0]LSDITK
CPTAC-684:
SERPING1.
DTFVN[+1.0]ASR
CPTAC-685:
PIGR.
VPGN[+1.0]VTAVLGETLK
CPTAC-686:
PTGDS.
SVVAPATDGGLN[+1.0]LTSTFLR
CPTAC-687:
KNG1.
LNAENN[+1.0]ATFYFK
CPTAC-688:
LAMP2.
LN[+1.0]SSTIK
CPTAC-689:
LAMP2.
VQPFN[+1.0]VTQGK
CPTAC-690:
VTN.
N[+1.0]GSLFAFR

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y7 (1+) 6.8 7 12.9 7.8 9.3 14.9 10.3 11.6 19.7 15 15 15
y6 (1+) 6.4 7.5 9.3 6.5 8.3 13.6 9.1 11.2 16.5 15 15 15
y5 (1+) 5.4 8.3 8.8 7.2 8.6 11.3 9 12 14.3 15 15 15
sum 4.8 6.8 9 5.9 7.9 12.4 7.6 10.4 15.3 15 15 15


Additional Resources and Comments


Assay Details for non-CPTAC-6100 Collapse assay details

Data source: Panorama

Official Gene Symbol
IGHG2
Peptide Sequence
GLPAPIEK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
206
Peptide End
213
CPTAC ID
non-CPTAC-6100
Peptide Molecular Mass
823.4804
Species
Homo sapiens (Human)
Assay Type
Direct PRM
Matrix
Bovine Serum Albumin
Submitting Laboratory
McGill University
Submitting Lab PI
Christoph H. Borchers, Gerald Batist

Publication

View Details (opens in a new window)

mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours. Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, Rene P Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Agilent 6495B QQQ-MS
Internal Standard
Standard Isotope labeled internal standard peptides with 13Cx, 15Ny (R+10 or K+8)
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Infinity 1290
Column Packing
commercial (Agilent ZORBAX Eclipse Plus C18)
Column Dimensions
4.6 mm × 150 mm, (5 µm)
Flow Rate
0.4 mL/min

Assay Multiplexing Expand assay panel

Johns Hopkins University-A

CPTAC-648:
APMAP.
AGPN[+1.0]GTLFVADAYK
CPTAC-649:
AFM.
DIENFN[+1.0]STQK
CPTAC-650:
AFM.
FN[+1.0]ETTEK
CPTAC-651:
SERPINA1.
YLGN[+1.0]ATAIFFLPDEGK
CPTAC-652:
APOB.
FN[+1.0]SSYLQGTNQITGR
CPTAC-653:
APOB.
YDFN[+1.0]SSM[+16.0]LYSTAK
CPTAC-654:
APOH.
VYKPSAGN[+1.0]NSLYR
CPTAC-655:
BTD.
FN[+1.0]DTEVLQR
CPTAC-656:
CDH13.
IN[+1.0]NTHALVSLLQNLNK
CPTAC-657:
CPB2.
QVHFFVN[+1.0]ASDVDNVK
CPTAC-658:
CTSD.
GSLSYLN[+1.0]VTR
CPTAC-659:
JCHAIN.
EN[+1.0]ISDPTSPLR
CPTAC-660:
CP.
EHEGAIYPDN[+1.0]TTDFQR
CPTAC-661:
CLU.
EDALN[+1.0]ETR
CPTAC-662:
CLU.
LAN[+1.0]LTQGEDQYYLR
CPTAC-663:
DKFZp779M0311.
QSVPAHFVALN[+1.0]GSK
CPTAC-664:
ATRN.
IDSTGN[+1.0]VTNELR
CPTAC-665:
C4A.
FSDGLESN[+1.0]SSTQFEVK
CPTAC-666:
C4A.
GLN[+1.0]VTLSSTGR
CPTAC-667:
C8A.
GGSSGWSGGLAQN[+1.0]R
CPTAC-668:
CD44.
AFN[+1.0]STLPTM[+16.0]AQM[+16.0]EK
CPTAC-669:
IGHG1.
EEQYN[+1.0]STYR
CPTAC-670:
LGALS3BP.
ALGFEN[+1.0]ATQALGR
CPTAC-671:
HP.
VVLHPN[+1.0]YSQVDIGLIK
CPTAC-672:
SERPINA4.
FLN[+1.0]DTM[+16.0]AVYEAK
CPTAC-673:
IGHG4.
EEQFN[+1.0]STYR
CPTAC-674:
IGHA2.
TPLTAN[+1.0]ITK
CPTAC-675:
IGHG2.
EEQFN[+1.0]STFR
CPTAC-676:
ITIH2.
GAFISN[+1.0]FSM[+16.0]TVDGK
CPTAC-677:
ICAM2.
AAPAPQEATATFN[+1.0]STADR
CPTAC-678:
LRG1.
LPPGLLAN[+1.0]FTLLR
CPTAC-679:
LYVE1.
ANQQLN[+1.0]FTEAK
CPTAC-680:
TIMP1.
FVGTPEVN[+1.0]QTTLYQR
CPTAC-681:
LCN2.
SYN[+1.0]VTSVLFR
CPTAC-682:
KLKB1.
IYPGVDFGGEELN[+1.0]VTFVK
CPTAC-683:
KLKB1.
IYSGILN[+1.0]LSDITK
CPTAC-684:
SERPING1.
DTFVN[+1.0]ASR
CPTAC-685:
PIGR.
VPGN[+1.0]VTAVLGETLK
CPTAC-686:
PTGDS.
SVVAPATDGGLN[+1.0]LTSTFLR
CPTAC-687:
KNG1.
LNAENN[+1.0]ATFYFK
CPTAC-688:
LAMP2.
LN[+1.0]SSTIK
CPTAC-689:
LAMP2.
VQPFN[+1.0]VTQGK
CPTAC-690:
VTN.
N[+1.0]GSLFAFR

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y2 (1+) 3.6 3.1 1.7 3.3 3.5 3 4.9 4.7 3.4 16 16 17
y4 (1+) 3.4 2.3 4.1 2.9 2.3 4.3 4.5 3.3 5.9 16 16 17
y5 (1+) 4.3 2.8 3.5 5 2.5 3.5 6.6 3.8 4.9 16 16 17
y6 (1+) 5.2 3.3 2.8 6 3.9 3.4 7.9 5.1 4.4 16 16 17
y6 (2+) 2.5 3.2 2.2 5.4 3.3 2 6 4.6 3 16 16 17
sum 2.2 1.9 1.4 4 2.1 1.4 4.6 2.8 2 16 16 17


Additional Resources and Comments